Russia's RDIF Agrees With Italy, Spain, France, Germany on Joint Sputnik V Production

© Photo : Press service of AFK "Sistema" / Go to the photo bankProduction of "Gam-COVID-Vac" vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia
Production of Gam-COVID-Vac vaccine against the coronavirus disease (COVID-19), developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), at Binnopharm pharmaceutical company in Zelenograd near Moscow, Russia - Sputnik International, 1920, 15.03.2021
Subscribe
US
India
Global
Last month, Hungary became the first nation in the European Union to approve the Russian vaccine. In March, the RDIF said that it could supply the bloc with the vaccine after approval by the European Medicines Agency (EMA).

The Russian Direct Investment Fund (RDIF), the promoter of Sputnik V abroad, has reached agreements with companies from Italy, Spain, France, and Germany to kick off joint production of the Russian vaccine, RDIF CEO Kirill Dmitriev announced on Monday.

"Currently there are additional talks ongoing to boost production in the EU. This will allow [us] to start supplying Sputnik V to the European single market once approval is granted by the European Medicines Agency (EMA)", Dmitriev said.

The RDIF chief added that the fund and its partners are poised to start supplies to those EU countries that independently authorise Sputnik V.

Empty vials of the second dose of the Sputnik V (Gam-COVID-Vac) vaccine are pictured at the San Martin hospital, in La Plata, on the outskirts of Buenos Aires, Argentina January 21, 2021. - Sputnik International, 1920, 09.03.2021
EU Regulator to Make Decisions on Sputnik V Vaccine Based Only On Scientific Data

Developed by the Gamaleya Research Institute and promoted by the Russian Direct Investment Fund, the Russian vaccine became the first registered anti-coronavirus drug in the world in August 2020. According to the analysis of phase III clinical trials, published in The Lancet, the vaccine has a 91.6% efficacy rate against COVID-19.

The medication has so far been approved for emergency use in 50 countries, including in several European nations, such as Hungary, Slovakia, Serbia, Montenegro, San Marino, and North Macedonia.

The European Medicines Agency is currently conducting a rolling review of the vaccine, which the RDIF said could be supplied to 50 million EU residents starting from June, as soon as the EMA signs off on its use.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала